Platelet responses to halothane in normal individuals and in patients susceptible to malignant hypothermia were evaluated. Platelets in platelet-rich plasma from both normal controls and patients underwent aggregation in response to halothane. There was no significant difference in the degree of aggregation between normal subjects and patients. Aggregation by halothane was associated with a change in platelet shape, centralization of platelet granules, and phosphorylation of platelet actin binding protein, myosin light chain, and a 40 000-dalton protein. Aggregation induced by halothane could be inhibited by EGTA, PGEj, adenosine and verapamil, but not by aspirin. Aggregation induced by halothane could be potentiated by small doses of adrenaline or ADP and in some individuals by caffeine. However, previous exposure of platelets to halothane made them subsequently less aggregable to ADP. The results of these studies do not support a use of halothane-induced aggregation of platelets to detect an abnormality in individuals susceptible to malignant hyperthermia, but do provide new evidence of the effects of halothane on cellular function.
The present studies were initiated in the hope of obtaining a simplified test to identify individuals susceptible to malignant hyperthermia, a disorder characterized by hyperpyrexia, muscle rigidity and generalized rhabdomyolysis in response to certain anaesthetic agents, particularly halothane (Gronert, 1980) . This genetic disorder is believed to involve a basic abnormality, not yet defined precisely, of skeletal muscle. Blood platelets have many similarities to muscle cells and it has been suggested that it may be possible to detect changes in their response to halothane (Solomons, McDermott and Mahowald, 1980; Solomons and Masson, 1982) . Since halothane can act as an agonist in terms of excitation-contraction coupling in skeletal muscle (Nelson and Denborough, 1977) , and a release of calcium from the platelet dense tubular system, a structure analagous to skeletal muscle sarcotubules, is believed to trigger changes in the shape and aggregation of platelets (Gerrard, Peterson and White, 1981) , we evaluated platelet aggregation in response to halothane in susceptible individuals and normal controls.
Malignant hyperthermia patients
Seven patients who had experienced documented episodes of malignant hyperthermia, muscle rigidity or hyperthermia, or both, on anaesthetic exposure associated with a marked increase in creatinine phosphokinase concentration were available for the present study.
Controls
Thirty-five apparently normal controls (23 male) (aged 15 -50 yr) with no personal or family history of malignant hyperthermia were studied.
Preparation of platelet-rich and platelet-poor plasma
Blood was obtained from the antecubital vein following informed consent, and anticoagulated immediately with heparin 30 u. ml" 1 . Platelet-rich plasma (PRP) was obtained by centrif ugation of the blood at 100 g for 20min. Platelet-poor plasma (PPP) was obtained by centrif ugation of the blood at 3000 g for 5 min. In some experiments, citrate anticoagulant (Gerrard et al., 1979) was evaluated also. (0.02-1% v/v) was then added to the PRP either directly in a few microlitres or indirectly following dilution of the halothane immediately beforehand in ethanol for the lower concentrations. After the addition of halothane to the PRP, the aggregometer vial was sealed with parafilm to decrease loss of halothane by vaporization. More than 0.5% ethanol was never added to the PRP. Inhibitors, when used, were added 30 s to 1 min before halothane. Percent aggregation was measured from the graph paper using the maximal extent of aggregation within 5 min of the addition of halothane.
Platelet electron microscopy and protein photphorylation
Samples for study of platelet ultrastructure were processed as previously described (Gerrard et al., 1979) , except that they were embedded in Spurr resin and evaluated using a Phillips 400 electron microscope. Platelet protein phosphorylation was evaluated as described previously (Carroll and Gerrard, 1982) following equilibration of the platelets with 32 P-orthophosphate for 1 h, washing the platelets once by addition of citrate anticoagulant 1 ml per ml PRP (Gerrard and Graff, 1980) , centrifuging at 1000# for 10 min at 4°C, and then resuspending the platelets in Hank's balanced salt solution pH 7.4 unit containing bovine serum albumin 1 mg ml" 1 (Sigma).
Reagents
Halothane, containing 0.01% thymol, and halothane with no thymol added were obtained from Halocarbon (Ontario) Ltd, Mai ton, Ontario.
Thymol, caffeine, adenosine, sodium heparin (from porcine intestinal mucosa) and aspirin were obtained from the Sigma Chemical Co. (St Louis, Mo.) and made up as solutions in Hank's balanced salt solution pH 7.4 unit or Tris-saline 0.1 mollitre" 1 , pH 7.4 unit. Dantrolene was kindly provided by Norwich-Eaton Ltd, Paris, Ontario and was made up as the sodium salt in Hank's balanced salt solution before use. ^-Orthophosphate was obtained from New England Nuclear.
RESULTS

Platelet aggregation in response to halothane
Platelets from patients with malignant hyperthermia were found to aggregate in response to halothane ( fig. 1 ) in a concentration-dependent fashion. Most individuals showed only a single reversible wave of aggregation, although a few showed a second wave also. Similar results were obtained with citrate as the anticoagulant. The aggregation response was not a result of the presence of thymol since halothane without thymol was also active, and thymol in concentrations similar to that present in the halothane had no effect. The effect on platelet aggregation was specific for halothane as neither enflurane nor suxamethonium caused either changes in platelet shape or aggregation. Initial studies suggested that normal controls might show less aggregation in response to halothane than individuals with malignant hyperthermia, but after analysis of the 35 normal individuals the difference between normals and patients became insignificant ( fig. 2 ). Numerous attempts to modify the assay to bring out larger differences between patients and normal individuals failed.
Characterization of the platelet response to halothane
In view of the widespread use of halothane as a general anaesthetic, we further evaluated the effects of halothane on platelets. Electron microscopy showed that platelets from patients with malignant hyperthermia were similar to those from normal patients ( fig. 3 ). The responses to halothane, of platelets from patients and normal individuals, were similar and involved an initial extension of pseudopods, a movement of the granules to the cell centres, and platelet adherence in aggregates similar to that seen with ADP or thrombin ( fig. 4) . Using platelet-rich plasma from most individuals, the aggregation in response to halothane reversed rapidly after the initial wave even under conditions where up to 60% aggregation was achieved during the first wave. In a few individuals there was a second wave of aggregation with the development of large aggregates. These large aggregates were similar to large ADP-or thrombin-stimulated aggregates except that, at the periphery of these aggregates, the platelets were relatively round with few pseudopods (fig. 5), while some had undergone a central movement of granules. The platelet aggregation in response to halothane was associated with stimulation of the phosphorylation of three platelet proteins, actin-binding protein, myosin light chain and a 40 000-dalton protein ( fig. 6 ). Platelet aggregation induced by halothane could be blocked by agents which inhibit platelets by increasing cell cyclic AMP concentration (PGEi, adenosine), by EGTA which chelates extracellular calcium ( fig. 7) , or by verapamil, an agent which interferes with membrane fluxes of calcium ( fig. 8 ). In contrast, aspirin 100 ^mol litre" 1 , which inhibits platelet prostaglandin synthesis, caused no inhibition of halothane-induced aggregation (first-wave aggregation only was tested). Dantrolene, a compound which blocks calcium release from the sarcotubules of skeletal muscle, produced 50-100% inhibition of halothane-induced aggregation depending on the donor, but only when used at a concentration of 2 mmol litre" 1 ( fig. 9 ). Caffeine, which inhibits platelet phosphodiesterase and is usually an inhibitor of platelet function, was found to have variable effects on the platelet response to halothane. In some individuals definite protentiation was found repeatedly with caffeine ( fig. 10) .
Addition of ADP or adrenaline with halothane potentiated the halothane response (figs 11, 12). However, when ADP was added after halothane, the response to ADP was decreased ( fig. 13 ).
DISCUSSION
The results of the present study show that platelets from both normal individuals and those susceptible to malignant hyperthennia will aggregate in response to halothane. The lack of a difference between the normal subjects and those susceptible to malignant hyperthermia would suggest either that the platelet is not involved in this disease, or that the defect is not in a component of the initial response, but rather of a later process. Two previous studies which evaluated platelet aggregation in response to ADP, adrenaline, collagen, arachidonic acid and A23187 also found no difference in the platelet aggregation response of normal subjects and those susceptible to malignant hyperthermia (Rosenberg et al., 1981; Sullivan, Ardlie and Denborough, 1982) .
The mechanism of the effect of halothane is of some interest. The present studies are consistent with the hypothesis that halothane acts to trigger a release of calcium from the dense tubular system to increase the cytoplasmic calcium concentration. Platelet aggregation and centralization of platelet granules can occur subsequent to an initiating intracellular flux of calcium (Gerrard, Peterson and White, 1981) . Phosphorylation of platelet proteins, particularly myosin light chain, has been shown to result from an increase in the cytoplasmic calcium concentration (Lyons and Shaw, 1980) . Specifically, calcium interacts with calmodulin to activate a protein kinase which is responsible for the phosphorylation event (Hathaway and Adelstein, 1979) . Our finding that halothane added to intact platelets stimulates phosphorylation of myosin light chain provides good evidence that one effect of halothane on platelets is to increase the cytoplasmic calcium concentration. Inhibition of the effect of halothane by verapamil, which can affect calcium fluxes (Tritthart, 1980) , and by agents which increase platelet cyclic AMP (which may also work through effects on calcium flux (Kaser-Glanzmann et al., 1977) ), are also consistent with the concept that halothane activates platelets by triggering a flux of calcium. The lack of effect of aspirin shows that the production of platelet prostaglandin and thromboxane is not necessary for the initial response to halothane. A role of halothane in increasing platelet cytoplasmic calcium concentrations, as proposed here, is similar to that proposed for the effects of halothane on liver cells (Zucker, Diamond and Berman, 1982) . Inhibition of halothane-induced aggregation by dantrolene was seen only at concentrations of dantrolene very high relative to those used to inhibit responses of skeletal muscle (Ellis and Carpenter, 1974) . It would appear that platelets, like cardiac muscle and intestinal smooth muscle (Butterfield and Ellis, 1973) , are affected minimally by dantrolene. Dantrolene may primarily inhibit a process involved in excitation-contraction coupling in skeletal muscle, which is less important in platelets. The lack of difference in halothane-induced platelet aggregation between normal individuals and those susceptible to malignant hyperthermia, and the weak effect of dantrolene suggest that the defect in malignant hyperthermia does not lie in a process important during the initial response of platelets. Thus, we must conclude that the low ATP concentration found by Solomons and Masson (1982) in patients susceptible to malignant hyperthermia following a prolonged (20-min) exposure of the platelets to halothane relates to an effect of halothane on a platelet process which is not a major component of this initial response. The action of dantrolene to prevent the above decrease in ATP concentration (Mahowald, Masson and Solomons, 1982) and the weak inhibitory effects of dantrolene on halothane-induced aggregation (this study) further support this conclusion. Potentiation of the effect of halothane by caffeine in some donors may be related to halothane potentiation of caffeine contracture in skeletal muscle. An effect of caffeine to release calcium from the platelet dense tubular system has not been described, but is possible. The variation in response from donor to donor may reflect the relative balance of an effect of caffeine to increase platelet cyclic AMP to inhibit platelet function and an effect of caffeine to stimulate an efflux of calcium from the platelet dense tubular system to promote platelet aggregation. Potentiation of halothane by adrenaline or ADP added together with halothane is similar to that seen with a number of other aggregating agents (Kinlough-Rathbone, Packham and Mustard, 1977; Rao, Reddy and White, 1981) . The basis for the refractoriness of halothane-exposed platelets to subsequent ADP-induced platelet aggregation is unknown, but could be related to an effect of halothane in increasing platelet cyclic AMP concentration (Walter et al., 1980) , and could explain the depressed responsiveness of platelets from individuals who have received halothane anaesthesia (Dalsgaard-Nielsen et al., 1981) . The relatively rounded appearance of platelets at the edge of large halothane-induced aggregates could also result from an inhibitory effect of halothane (perhaps mediated by cyclic AMP) which takes longer to develop than the initial stimulating effects.
While these findings do not provide a basis for distinguishing between normal individuals and those with malignant hyperthermia, they extend our knowledge of the effects of halothane on cells and may provide the background for further investigations into the nature of malignant hyperthermia. 
L'HALOTHANE STIMULE L'AGGREGATION PLAQUETTAIRE A LA FOIS CHEZ LES INDIVIDUS NORMAUX ET CHEZ CEUX
EL HALOTANO ESTIMULA EL AGREGO DE PLAQUETAS TANTO EN INDIVIDUOS NORMALES COMO EN LOS SUSCEPTIBLES
A HIPERTERMIA MALIGNA SUMARIO Se cvaluaron las respuestas de las plaquetas «i halotano en individuos normales y en pacientes susceptibles a la hipertermia maligna Las plaquetas en el plasma rico en plaquetas tanto de los controles normales como de los pacientes se agregaron en respuesta al halotano. No hubo diferencia significativa en el grado de agregacidn entre los sujetos normales y los pacientes. El agrego por halotano se hallo asociado con un cambio en la forma de las plaquetas, la centralization de los granulos de las plaquetas y la fosforilacidn de la proteina ligadora actina de las plaquetas, de la cadena ligera de miosina y de la proteina dalton-40.000. El agrego inducido por cl halotano pudo ser inhibido por EGTA, PGEj, adenosina y verapamil, pero no asi por la (spirina. El agrego inducido por cl halotano pudo scr aumentado por pequenas dosis dc adrcnalina o ADP y en algunos pacientes por cafeina. Sin embargo, la exposici6n anterior de las plaquetas al halotano hizo que en lo sucesivo las plaquetas fueron menos sensitivas al ADP. Los resultados de esos estudios no apoyan el uso de la agregacion de plaquetas inducida por halotano para detectar lai anomalias en individuos susceptibles a la hipertermia maligna pero »i dan una nueva prueba de los efectos del halotano sobre la fund6n celular.
